NEW YORK (GenomeWeb News) – Oncology diagnostics company Biocept said on Friday that its revenues for 2013 increased 23 percent year over year.

For full-year 2013, revenues rose to $134,245 from $109,289 in 2012, the San Diego-based firm said in its Form 10-K filed with the US Securities and Exchange Commission. Its net loss in 2013 was $9.2 million, or $50.80 per share, compared to a net loss of $12.3 million, or $76.43 per share, in 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.